Lora-Tamayo, 8,553 patient HCQ late treatment study: 50% lower mortality [p<0.0001] https://c19p.org/loratamayo
copied to clipboard
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
et al., J. Infection, doi:10.1016/j.jinf.2021.02.011
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
|
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7,192, control 1,361, odds ratio converted to relative risk, univariate, control prevalence approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lora-Tamayo et al., 2/11/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.